Sunnyvale, CA, ‐ October 31, 2019 ‐ JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules. The agreement will focus on the development of a glyco-affinity ligand and capture resin.
PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography
TOKYO, JAPAN – September 20, 2019 - JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.
Sunnyvale, CA – July 11, 2019 – JSR Life Sciences, LLC announced today that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC. The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training.
SUNNYVALE, CA – Mar. 14, 2019 – JSR announced today that it will establish a US headquarters for its biotechnology and life sciences focused businesses under the name JSR Life Sciences, LLC effective April 1, 2019. The formation of JSR Life Sciences will centralize leadership and resources to support the company’s value proposition of driving innovation to provide a portfolio of integrated products, services and technologies to help partners develop and commercialize therapeutics and diagnostics that benefit global human health.
Vancouver, Canada - September 18, 2018 - Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.